Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be a male aged 18 or older
- You must be willing to sign a consent form, including agreeing to provide blood samples for DNA testing
- You must have prostate cancer that has spread to other parts of the body and still responds to hormone treatment (either newly diagnosed at this stage or having progressed from an earlier stage)
- Your cancer must be classified as high-grade, meaning it is considered aggressive (Gleason score of 8, 9, or 10)
- Your cancer must have spread widely, meaning you have 4 or more bone tumours (with at least one outside the spine or pelvis) and/or at least one tumour in an organ such as the liver or lungs
- Your past medical records and documentation must be available
- You must already have a known result from a tumour tissue test showing whether you carry certain gene changes linked to DNA repair (called HRR mutations) (confirm with trial site)
Who may not be able to join:
- You may not be able to join if you have already taken part in another clinical trial since being diagnosed with prostate cancer that has spread
- You may not be able to join if your cancer has already progressed to a stage where it no longer responds to hormone treatment (known as castration-resistant prostate cancer)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients received any ADT; Proportion of patients received ADT by each type and by each drug; Proportion of patients received first generation antiandrogens; Proportion of patients received androgen receptor pathway inhibitors (ARPI) at mHSPC; Duration of ARPI therapy; Proportion of patients received any chemotherapy at mHSPC; Duration of chemotherapy; Proportion of patients received radiation therapy; Proportion of patients with each radiation area; Proportion of patients underwent surgery at mHSPC; Proportion of patients received triplet therapy at mHSPC; Time from mPC diagnosi...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.